{"DataElement":{"publicId":"5082027","version":"1","preferredName":"Antipneumocystis Agent Administered Type","preferredDefinition":"A description of the antipneumocystis agent that was administered.","longName":"5081203v1.0:5081195v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5081203","version":"1","preferredName":"Antipneumocystis Agent Administered","preferredDefinition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP)._The act of having given something (e.g., a medication or test).","longName":"5081201v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5081201","version":"1","preferredName":"Antipneumocystis Agent","preferredDefinition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","longName":"C124791","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antipneumocystis Agent","conceptCode":"C124791","definition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD9A-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BDA8-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5081195","version":"1","preferredName":"Antipneumocystis Agent Type","preferredDefinition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP)._Something distinguishable as an identifiable class based on common qualities.","longName":"5081195v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BCCD-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Other anti-pneumocystis","valueDescription":"Other Antipneumocystis Agent","ValueMeaning":{"publicId":"5081196","version":"1","preferredName":"Other Antipneumocystis Agent","longName":"5081196","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antipneumocystis Agent","conceptCode":"C124791","definition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BCDA-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BCF3-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Pentamidine IV","valueDescription":"Intravenous Route of Administration Pentamidine","ValueMeaning":{"publicId":"5081197","version":"1","preferredName":"Intravenous Route of Administration Pentamidine","longName":"5081197","preferredDefinition":"Administration within or into a vein or veins.: A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD00-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD19-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Pentamidine inhaled","valueDescription":"Inhalation Route of Administration Pentamidine","ValueMeaning":{"publicId":"5081198","version":"1","preferredName":"Inhalation Route of Administration Pentamidine","longName":"5081198","preferredDefinition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.: A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inhalation Route of Administration","conceptCode":"C38216","definition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD26-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD3F-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Dapsone","valueDescription":"Dapsone","ValueMeaning":{"publicId":"5081199","version":"1","preferredName":"Dapsone","longName":"5081199","preferredDefinition":"A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dapsone","conceptCode":"C415","definition":"A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD49-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD61-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Atovaquone","valueDescription":"Atovoquone","ValueMeaning":{"publicId":"2575655","version":"1","preferredName":"Atovoquone","longName":"2575655","preferredDefinition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atovaquone","conceptCode":"C28838","definition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F494-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"CURTIST","dateModified":"2010-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD6B-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"},{"value":"Trimethoprim/Sulfamethoxazole","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"5081200","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"5081200","preferredDefinition":"An antibiotic drug used to treat infection and prevent pneumocystis carinii pneumonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BD75-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"267C5BAC-BD8D-C815-E050-BB89AD436117","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5081194","version":"1","preferredName":"Antipneumocystis Agent Type","preferredDefinition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).:Something distinguishable as an identifiable class based on common qualities.","longName":"C124791:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antipneumocystis Agent","conceptCode":"C124791","definition":"Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BCA6-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"ONEDATA","dateModified":"2015-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BCB7-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_IP_antipneumo_agnt_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Anti-pneumocystis (PJP) drug","type":"Application Standard Question Text","description":"Anti-pneumocystis (PJP) drug","url":null,"context":"NHLBI"},{"name":"What was the antipneumocystis","type":"Preferred Question Text","description":"What was the antipneumocystis agent that was administered?","url":null,"context":"NHLBI"},{"name":"Anti-pneumocystis (PJP) drug","type":"Alternate Question Text","description":"Anti-pneumocystis (PJP) drug","url":null,"context":"NHLBI"},{"name":"Specify the first anti-pneumocystis (PJP) drug given","type":"Alternate Question Text","description":"Specify the first anti-pneumocystis (PJP) drug given","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"267C5BAC-BDBB-C815-E050-BB89AD436117","latestVersionIndicator":"Yes","beginDate":"2015-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-09","modifiedBy":"MALUMK","dateModified":"2021-03-25","changeDescription":".AQT added for 2100r7. 03/25/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}